nach oben

Inflammopharmacology

Erschienen in:

01.10.2012 | Review

A review of the pharmacobiotic regulation of gastrointestinal inflammation by probiotics, commensal bacteria and prebiotics

verfasst von: L. Vitetta, D. Briskey, E. Hayes, C. Shing, J. Peake

Erschienen in: Inflammopharmacology | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

The idea that microbes induce disease has steered medical research toward the discovery of antibacterial products for the prevention and treatment of microbial infections. The twentieth century saw increasing dependency on antimicrobials as mainline therapy accentuating the notion that bacterial interactions with humans were to be avoided or desirably controlled. The last two decades, though, have seen a refocusing of thinking and research effort directed towards elucidating the critical inter-relationships between the gut microbiome and its host that control health/wellness or disease. This research has redefined the interactions between gut microbes and vertebrates, now recognizing that the microbial active cohort and its mammalian host have shared co-evolutionary metabolic interactions that span millennia. Microbial interactions in the gastrointestinal tract provide the necessary cues for the development of regulated pro- and anti-inflammatory signals that promotes immunological tolerance, metabolic regulation and other factors which may then control local and extra-intestinal inflammation. Pharmacobiotics, using nutritional and functional food additives to regulate the gut microbiome, will be an exciting growth area of therapeutics, developing alongside an increased scientific understanding of gut-microbiome symbiosis in health and disease.

Literally meaning eating at the same table.

A placebo is a substance containing no medication benefit and prescribed to reinforce a patient’s expectation of possibly attaining a beneficial effect.

AlFaleh KM, Bassler D (2010) Cochrane review: probiotics for prevention of necrotizing enterocolitis in preterm infants. Evid Based Child Health 5:339–368CrossRef

Bach JF (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. NEJM 347(12):911–920PubMedCrossRef

Backhead F, Manchester JK, Semenkovich CF, Gordon JI (2007) Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. PNAS USA 104:979–984CrossRef

Bauer H, Horowitz RE, Levenson SM et al (1963) The response of the lymphatic tissue to the microbial flora. Studies on germfree mice. Am J Pathol 42:471–483PubMed

Bengmark S, Martindale R (2005) Prebiotics and synbiotics in clinical medicine. Nutr Clin Pract 20(2):244–261PubMedCrossRef

Berg RD, Savage DC (1975) Immune responses of specific pathogen-free and gnotobiotic mice to antigens of indigenous and nonindigenous microorganisms. Infect Immun 11(2):320–329PubMed

Betsi GI, Papadavid E, Falagas ME et al (2008) Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. Am J Clin Dermatol 9(2):93–103PubMedCrossRef

Buddington RK, Williams CH, Chen SC et al (1996) Dietary supplement of neosugar alters the fecal flora and decreases activities of some reductive enzymes in human subjects. Am J Clin Nutr 63(5):709–716PubMed

Cain AM, Karpa KD (2011) Clinical utility of probiotics in inflammatory bowel disease. Altern Ther Health Med 17(1):72–79PubMed

Caselli M, Vaira G, Calo G et al (2011) Structural bacterial molecules as potential candidates for an evolution of the classical concept of probiotics. Adv Nutr 2:372–376PubMed

Cert-Bensussan N, Gaboriau-Routhiau V (2010) The immune system and the gut microbiota: friends or foes? Nat Rev Immunol 10(10):735–744CrossRef

Chapman CM, Gibson GR, Rowland I (2011) Health benefits of probiotics: are mixtures more effective than single strains? Eur J Nutr 50(1):1–17PubMedCrossRef

Chmielewska A, Szajewska H (2010) Systematic review of randomised controlled trials: probiotics for functional constipation. World J Gastroenrol 16(1):69–75

Chouraqui JP, Grathwohl D, Labaune JM et al (2008) Assessment of the safety, tolerance, and protective effect against diarrhea of infant formulas containing mixtures of probiotics or probiotics and prebiotics in a randomized controlled trial. AJCN 87(5):1365–1373

Cimperman L, Bayless G, Best K et al (2011) A randomized, double-blind, placebo-controlled pilot study of Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhea in hospitalized adults. J Clin Gastroenterol 45(9):785–789PubMedCrossRef

Collier-Hyams LS, Sloane V, Batten BC, Neish AS (2005) Cutting edge: bacterial modulation of epithelial signaling via changes in neddylation of cullin-1. J Immunol 175(7):4194–4198PubMed

Cremonini F, Di Caro S, Covino M et al (2002) Effect of different probiotic preparations on anti-Helicobacter pylori therapy related side effects: a parallele group, triple blind, placebo controlled study. Am J Gastroenterol 97:2744–2749PubMedCrossRef

Davidson LE, Fiorino AM, Snydman DR, Hibberd PL (2011) Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial. Eur J Clin Nutr 65(4):501–507PubMedCrossRef

de Vrese M, Marteau PR (2007) Probiotics and prebiotics: effects on diarrhea. J Nutr 137(3 Suppl 2):803S–811SPubMed

de Vrese M, Schrezenmeir J (2008) Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol 111:1–66PubMed

Delia P, Sansotta G, Donato V et al (2007) Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol 13(6):912–915PubMed

Dominguez-Bello MG et al (2010) Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. PNAS 107:11971–11975PubMedCrossRef

Drouault-Holowacz S, Bieuvelet S, Burckel A et al (2008) A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol 32(2):147–152PubMedCrossRef

Duchmann R, Kaiser I, Hermann E et al (1995) Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 102:448–455

Eckmann L (2006) Sensor molecules in intestinal innate immunity against bacterial infections. Curr Opin Gastroenterol 22(2):95–101PubMedCrossRef

Enck P, Zimmermann K, Menke G et al (2008) A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome—a randomized controlled trial with primary care physicians. Neurogastroenterol Motil 20(10):1103–1109PubMedCrossRef

Falagas ME, Betsi GI, Athanasiou S (2006) Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. J Antimicrob Chemother 58(2):266–272PubMedCrossRef

Fedorak RN, Dieleman LA (2008) Probiotics in the treatment of human inflammatory bowel diseases. J Clin Gastroenterol 42(Suppl 2):S97–S103

Forestier C, Guelon D, Cluytens V et al (2008) Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients. Crit Care 12(3):R69PubMedCrossRef

Francavilla R, Lionetti E, Castellaneta SP et al (2008) Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter 13(2):127–134PubMedCrossRef

Frank DN, Robertson CE, Hamm CM et al (2011) Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 17(1):179–184PubMedCrossRef

Friedman G, George J (2000) Treatment of refractory pouchitis with probiotic and probiotic therapy. Gastroenterology 118:A4167CrossRef

Frohmader TJ, Chaboyer WP, Robertson IK, Gowardman J (2010) Decrease in frequency of liquid stool in enterally fed critically ill patients given the multispecies probiotic VSL#3: a pilot trial. Am J Crit Care 19(3):e1–e11PubMedCrossRef

Fuller R (1989) Probiotics in man and animals. J Appl Bacteriol 66(5):365–378PubMedCrossRef

Furrie E, Macfarlane S, Kennedy A et al (2005) Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 54:242–249PubMedCrossRef

Fuss IJ, Neurath M, Boirivant M et al (1996) Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157(3):1261–1270PubMed

Giaffer MH, Holdsworth CD, Duerden BI (1991) The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. J Med Microbiol 35(4):238–243PubMedCrossRef

Gionchetti P, Rizzello F, Venturi A et al (2000a) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double blind, placebo controlled trial. Gastroenterology 119:305–309PubMedCrossRef

Gionchetti P, Rizzello F, Venturi A et al (2000b) Probiotics in infective diarrhoea and inflammatory bowel diseases. J Gastroenterol Hepatol 15(5):489–493PubMedCrossRef

Gionchetti P, Rizzello F, Helwig U et al (2003) Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebocontrolled trial. Gastroenterology 124:1202–1209PubMedCrossRef

Giovannini M, Agostoni C, Riva E et al (2007) A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis. Pediatr Res 62(2):215–220PubMedCrossRef

Guandalini S (2011) Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol 45(Suppl):S149–S153PubMedCrossRef

Guandalini S, Magazzu G, Chiaro A et al (2010) VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind. Crossover study. J Pediatr Gastroenterol Nutr 51(1):24–30PubMedCrossRef

Hammer HF (2011) Gut microbiota and inflammatory bowel disease. Dig Dis 29(6):550–553PubMedCrossRef

Hao Q, Lu Z, Dong BR et al (2011) Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev 9:CD006895

Hatakka K, Savilahti E, Pönkä A et al (2001) Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ 322(7298):1327PubMedCrossRef

Hawrelak JA, Whitten DL, Myers SP (2005) Is Lactobacillus rhamnosus GG effective in preventing the onset of antibiotic-associated diarrhoea: a systematic review. Digestion 72(1):51–56PubMedCrossRef

Heller F, Florian P, Bojarski C et al (2005) Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterol 129(2):550–564

Hickson M (2011) Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Therap Adv Gastroenterol 4(3):185–197PubMedCrossRef

Hooper LV (2004) Bacterial contributions to mammalian gut development. Trends Microbiol 12:129–134PubMedCrossRef

Hooper LV, Macpherson AJ (2010) Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol 10(3):159–169PubMedCrossRef

Hummelen R, Changalucha J, Butamanya NL et al (2011) Effect of 25 weeks probiotic supplementation on immune function of HIV patients. Gut Microbes 2(2):80–85PubMedCrossRef

Hussaarts L, van der Vlugt LE, Yazdanbakhsh M, Smits HH (2011) Regulatory B-cell induction by helminths: implications for allergic disease. J Allergy Clin Immunol 128(4):733–739PubMedCrossRef

Hvas CL, Kelsen J, Agnholt J et al (2007) Crohn’s disease intestinal CD4 + T cells have impaired interleukin-10 production which is not restored by probiotic bacteria. Scand J Gastroenterol 42(5):592–601PubMedCrossRef

Ivison SM, Wang C, Himmel ME et al (2010) Oxidative stress enhances IL-8 and inhibits CCL20 production from intestinal epithelial cells in response to bacterial flagellin. Am J Physiol Gastrointest Liver Physiol 299(3):G733–G741PubMedCrossRef

Johnston BC, Goldenberg JZ, Vandvik PO et al (2011) Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 11:CD004827

Kabelitz D, Wesch D, Oberg HH (2006) Regulation of regulatory T cells: role of dendritic cells and toll-like receptors. Crit Rev Immunol 26(4):291–306PubMedCrossRef

Kajander K, Hatakka K, Poussa T et al (2005) A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 22(5):387–394PubMedCrossRef

Kajander K, Myllyluoma E, Rajilic-Stojanovic M et al (2008) Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 27(1):48–57PubMedCrossRef

Kalliomaki M, Salminen S, Arvilommi H et al (2001) Probiotics in primary prevention of atopic disease: a randomised placebo controlled trial. Lancet 357:1076–1079PubMedCrossRef

Kalliomaki M, Salminen S, Poussa T et al (2003) Probiotics and prevention of atopic disease: 4 year follow up of randomised placebo controlled trial. Lancet 361:1867–1871CrossRef

Kalliomäki M, Salminen S, Poussa T et al (2007) Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol 119(4):1019–1021PubMedCrossRef

Ki Cha B, Mun Jung S, Hwan Choi C et al (2011) The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol [Epub ahead of print]

Kim HJ, Camilleri M, McKinzie S et al (2003) A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 17(7):895–904PubMedCrossRef

Kim HJ, Vazquez Roque MI, Camilleri M (2005) A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 17(5):687–696PubMedCrossRef

Koduganti RR, Sandeep N, Guduguntla S et al (2011) Probiotics and prebiotics in periodontal therapy. Indian J Dent Res 22(2):324–330PubMedCrossRef

Kontiokari T, Sundqvist K, Nuutinen M et al (2001) Randomised trial of cranberry–lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 322:1571–1573PubMedCrossRef

Kukkonen K, Savilahti E, Haahtela T et al (2007) Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 119(1):192–198PubMedCrossRef

Kumar A, Wu H, Collier-Hyams LS et al (2007) Commensal bacteria modulate cullin-dependent signaling via generation of reactive oxygen species. EMBO J 26(21):4457–4466PubMedCrossRef

Lakatos PL, Fischer S, Lakatos L et al (2006) Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take “toll”? World J Gastroenterol 12(12):1829–1841PubMed

Lee BJ, Bak YT (2011) Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil 17(3):252–266PubMedCrossRef

Lesbros-Pantoflickova D, Corthesy-Theulaz I, Blum AL (2007) Helicobacter pylori and probiotics. J Nutr 137(3 Suppl 2):812S–818SPubMed

Ley RE, Hamady M, Lozupone C et al (2008) Evolution of mammals and their gut microbes. Science 320:1647–1651PubMedCrossRef

Lin JS, Chiu YH, Lin NT et al (2009) Different effects of probiotic species/strains on infections in preschool children: a double-blind, randomized, controlled study. Vaccine 27(7):1073–1079PubMedCrossRef

Lindsay JO, Whelan K, Stagg AJ et al (2006) Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn’s disease. Gut 55:348–355PubMedCrossRef

Linnane AW, Kios M, Vitetta L (2007) Healthy aging: regulation of the metabolome by cellular redox modulation and prooxidant signaling systems: the essential roles of superoxide anion and hydrogen peroxide. Biogerontology 8(5):445–467PubMedCrossRef

Lomax AR, Calder PC (2009) Probiotics, immune function, infection and inflammation: a review of the evidence from studies conducted in humans. Curr Pharm Des 15(13):1428–1518PubMedCrossRef

Mack DR (2011) Probiotics in inflammatory bowel diseases and associated conditions. Nutrients 3(2):245–264PubMedCrossRef

Mackay IR, Rosen FS, Zinkernagel RM (2001) Maternal antibodies, childhood infections, and autoimmune diseases. NEJM 345(18):1331–1335CrossRef

Madden JA, Hunter JO (2002) A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Br J Nutr 88:S67–S72PubMedCrossRef

Majamaa H, Isolauri E (1997) Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol 99:179–185PubMedCrossRef

Mañé J, Pedrosa E, Lorén V et al (2011) A mixture of Lactobacillus plantarum CECT 7315 and CECT 7316 enhances systemic immunity in elderly subjects. A dose-response, double-blind, placebo-controlled, randomized pilot trial. Nutr Hosp 26:228–235PubMed

Martin HM, Campbell BJ, Hart CA et al (2004) Enhanced Escherichia coli adherence and invasion in Crohn’s disease and colon cancer. Gastroenterol 127:80–93CrossRef

Matsuoka K, Inoue N, Sato T et al (2004) T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn’s disease. Gut 53(9):1303–1308PubMedCrossRef

Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL (2005) An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122(1):107–118PubMedCrossRef

Mazmanian SK, Round JL, Kasper DL (2008) A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453:620–625PubMedCrossRef

Mencarelli A, Distrutti E, Renga B et al (2011) Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One 6(7):e22978PubMedCrossRef

Mimura T, Rizzello F, Helwig U et al (2004) Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53:108–114PubMedCrossRef

Mourad-Baars P, Hussey S, Jones NL (2010) Helicobacter pylori infection and childhood. Helicobacter 15(Suppl 1):53–59PubMedCrossRef

Mow WS, Vasiliauskas EA, Lin Y et al (2004) Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease. Gastroenterology 126:414–424

Mukerji SS, Pynnonen MA, Kim HM et al (2009) Probiotics as adjunctive treatment for chronic rhinosinusitis: a randomized controlled trial. Otolaryngol Head Neck Surg 140(2):202–208PubMedCrossRef

Mylonaki M, Rayment NB, Rampton DS et al (2005) Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. Inflamm Bowel Dis 11(5):481–487PubMedCrossRef

Nagata S, Asahara T, Ohta T (2011) Effect of the continuous intake of probiotic-fermented milk containing Lactobacillus casei strain Shirota on fever in a mass outbreak of norovirus gastroenteritis and the faecal microflora in a health service facility for the aged. Br J Nutr 106(4):549–556PubMedCrossRef

Naito S, Koga H, Yamaguchi A et al (2008) Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of bladder cancer. J Urol 179(2):485–490PubMedCrossRef

Näse L, Hatakka K, Savilahti E et al (2001) Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res 35(6):412–420PubMedCrossRef

Niedzielin K, Kordecki H, Birkenfeld B (2001) A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 13(10):1143–1147PubMedCrossRef

Niv E, Naftali T, Hallak R, Vaisman N (2005) The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome—a double blind, placebo-controlled, randomized study. Clin Nutr 24(6):925–931PubMedCrossRef

Nunbhakdi-Craig V, Machleidt T, Ogris E et al (2002) Protein phosphatase 2A associates with and regulates atypical PKC and the epithelial tight junction complex. J Cell Biol 158(5):967–978PubMedCrossRef

O’Hara AM, Shanahan F (2006) The gut flora as a forgotten organ. EMBO Rep 7(7):688–693PubMedCrossRef

O’Mahony L, McCarthy J, Kelly P et al (2005) Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128(3):541–551PubMedCrossRef

O’Neill LA (2006) How Toll-like receptors signal: what we know and what we don’t know. Curr Opin Immunol 18:3–9PubMedCrossRef

Parassol N, Freitas M, Thoreux K et al (2005) Lactobacillus casei DN-114 001 inhibits the increase in paracellular permeability of enteropathogenic Escherichia coli-infected T84 cells. Res Microbiol 156(2):256–262PubMedCrossRef

Pasare C, Medzhitov R (2004) Toll-dependent control mechanisms of CD4 T cell activation. Immunity 21:733–741PubMedCrossRef

Paul G, Khare V, Gasche C (2011) Inflamed gut mucosa: downstream of interleukin-10. Eur J Clin Invest. doi:10.1111/j.1365-2362.2011.02552.x PubMed

Pickering GW (1950) Significance of the discovery of the effects of cortisone on rheumatopid arthritis. Lancet 2(6620):81–84

Pineiro M, Stanton C (2007) Probiotic bacteria: legislative framework—requirements to evidence basis. J Nutr 137(3 Suppl 2):850S–853SPubMed

Prisciandaro LD, Geier MS, Butler RN et al (2011) Evidence supporting the use of probiotics for the prevention and treatment of chemotherapy-induced intestinal mucositis. Crit Rev Food Sci Nutr 51(3):239–247PubMedCrossRef

Quigley EM (2011) The enteric microbiota in the pathogenesis and management of constipation. Best Pract Res Clin Gastroenterol 25(1):119–126PubMedCrossRef

Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R (2004) Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118(2):229–241PubMedCrossRef

Rao AV, Bested AC, Beaulne TM et al (2009) A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog 1(1):6PubMedCrossRef

Rohde CL, Bartolini V, Jones N (2009) The use of probiotics in the prevention and treatment of antibiotic-associated diarrhea with special interest in Clostridium difficile-associated diarrhea. Nutr Clin Pract 24(1):33–40PubMedCrossRef

Rossi O, van Baarlen P, Wells JM (2011) Host-recognition of pathogens and commensals in the mammalian intestine. Curr Top Microbiol Immunol [Epub ahead of print]

Saavedra JM, Bauman NA, Oung I et al (1994) Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 344:1046–1049PubMedCrossRef

Sairanen U, Piirainen L, Nevala R, Korpela R (2007) Yoghurt containing galacto-oligosaccharides, prunes and linseed reduces the severity of mild constipation in elderly subjects. Eur J Clin Nutr 61(12):1423–1428PubMedCrossRef

Sartor RB (2005) Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nature Clin Prac Gastroenterol Hepatol 3(7):394–407

Sator RB (2006) Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nature Clin Prac Gastroenterol Hepatol 3(7):390–407

Savino F, Pelle E, Palumeri E et al (2007) Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics 119(1):e124–e130PubMedCrossRef

Savino F, Cordisco L, Tarasco V et al (2010) Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics 126:e526–e533PubMedCrossRef

Scheppach W, Luehrs H, Menzel T (2001) Beneficial health effects of low-digestible carbohydrate consumption. Br J Nutr 85(Suppl 1):S23–S30PubMedCrossRef

Schneeberger EE, Lynch RD (2004) The tight junction: a multifunctional complex. Am J Physiol Cell Physiol 286(6):C1213–C1228PubMedCrossRef

Scholz-Ahrens KE, Ade P, Marten B et al (2007) Prebiotics, probiotics, and synbiotics affect mineral absorption, bone mineral content, and bone structure. J Nutr 137(3 Suppl 2):838S–846SPubMed

Shadid R, Haarman M, Knol J et al (2007) Effects of galactooligosaccharide and long-chain fructooligosaccharide supplementation during pregnancy on maternal and neonatal microbiota and immunity—a randomized, double-blind, placebo-controlled study. AJCN 86(5):1426–1437

Shaw SY, Blanchard JF, Bernstein CN (2011) Association between the use of antibiotics and new diagnoses of Crohn’s disease and ulcerative colitis. Am J Gastroenterol. doi:10.1038/ajg.2011.304 PubMed

Shornikova AV, Casas IA, Mykkänen H et al (1997) Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J 16(12):1103–1107PubMedCrossRef

Sinn DH, Song JH, Kim HJ et al (2008) Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 53(10):2714–2718PubMedCrossRef

Sironi M, Clerici M (2010) The hygiene hypothesis: an evolutionary perspective. Microbes Infect 12(6):421–427PubMedCrossRef

Slawik S, Staufenbiel I, Schilke R et al (2011) Probiotics affect the clinical inflammatory parameters of experimental gingivitis in humans. Eur J Clin Nutr 65(7):857–863PubMedCrossRef

Sullivan A, Nord CE, Evengård B (2009) Effect of supplement with lactic-acid producing bacteria on fatigue and physical activity in patients with chronic fatigue syndrome. Nutr J 26(8):4CrossRef

Swidsinski A, Ladhoff A, Pernthaler A et al (2002) Mucosal flora in inflammatory bowel disease. Gastroenterol 122(1):44–54CrossRef

Tabbers MM, Chmielewska A, Roseboom MG et al (2009) Effect of the consumption of a fermented dairy product containing Bifidobacterium lactis DN-173 010 on constipation in childhood: a multicentre randomised controlled trial (NTRTC: 1571). BMC Pediatr 9:22PubMedCrossRef

Talley NJ, Abreu MT, Achkar JP et al (2011) An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 106(Suppl 1):S2–S25; quiz S26

Tappenden KA, Deutsch AS (2007) The physiological relevance of the intestinal microbiota—contributions to human health. JACN 26(6):679S–683S

Twetman S, Stecksen-Blicks C (2008) Probiotics and oral health effects in children. Int J Paediatr Dent 18:3–10PubMed

Van de Merwe JP, Schroder AM, Wensinck F et al (1988) The obligate anaerobic faecal flora of patients with Crohn’s disease and their first-degree relatives. Scand J Gastroenterol 23(9):1125–1131PubMedCrossRef

Vitetta L, Sali A (2008) Probiotics, prebiotics and gastrointestinal health. Med Today 9:65–70

Welters CF, Heineman E, Thunnissen FB et al (2002) Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum 45(5):621–627PubMedCrossRef

Wen L, Ley RE, Volchkov PY et al (2008) Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 455:1109–1113PubMedCrossRef

Whorwell PJ, Altringer L, Morel J et al (2006) Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 101(7):1581–1590PubMedCrossRef

Wills-Karp M, Santeliz J, Karp CL (2001) The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat Rev Immunol 1:69–75PubMedCrossRef

Wu JT, Lin HC, Hu YC, Chien CT (2005) Neddylation and deneddylation regulate Cul1 and Cul3 protein accumulation. Nat Cell Biol 7(10):1014–1020PubMedCrossRef

Xu J, Gordon JI (2003) Inaugural article: honor thy symbionts. PNAS 100:10452–10459PubMedCrossRef

Yen CH, Kuo YW, Tseng YH et al (2011) Beneficial effects of fructo-oligosaccharides supplementation on fecal bifidobacteria and index of peroxidation status in constipated nursing-home residents—a placebo-controlled, diet-controlled trial. Nutrition 27(3):323–328PubMedCrossRef

Zeng J, Li YQ, Zuo XL et al (2008) Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 28(8):994–1002PubMedCrossRef

Zyrek AA, Cichon C, Helms S et al (2007) Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 9:804–816PubMedCrossRef

Titel: A review of the pharmacobiotic regulation of gastrointestinal inflammation by probiotics, commensal bacteria and prebiotics
verfasst von: L. Vitetta
D. Briskey
E. Hayes
C. Shing
J. Peake
Publikationsdatum: 01.10.2012
Verlag: SP Birkhäuser Verlag Basel
Erschienen in: Inflammopharmacology / Ausgabe 5/2012
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-012-0126-8

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2012

Systemic alcohol-protective effects of quercetin besides its ameliorating effect on alcohol-induced neuropathic pain

Protective effect of aqueous extract of Spinacia oleracea leaves in experimental paradigms of inflammatory bowel disease

Atorvastatin inhibits the inflammatory response caused by anti-M3 peptide IgG in patients with primary Sjögren’s syndrome

Some applications of pharmacogenomics and epigenetics in drug development and use in pursuit of personalized medicine

Effect of propolis on mast cells in wound healing